RxDoctor Payments Data

Jad Sallit, MD

Internal Medicine · Irwin, PANPI 1316501141

Payments from drug & device makers

$1,250in general payments, 2019–2025

Across 63 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$184
  • Pfizer$149
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • Novo Nordisk$121
  • AstraZeneca$87
  • Lilly USA, LLC$71
  • plus $499 from 19 others

What the payments were for

  • Food & beverage$1,250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,250 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$104,416
Medicare patients
193
Services billed
839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$55,913
RexultiBrexpiprazole28$35,348
JardianceEmpagliflozin18$14,993
FarxigaDapagliflozin Propanediol17$12,775
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,492
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$11,827
TradjentaLinagliptin15$8,929
XareltoRivaroxaban19$7,864
JanuviaSitagliptin Phosphate18$7,857
Ramelteon17$3,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$2,609
Duloxetine Hcl45$2,513
Unifine Safecontrol Pen NeedlePen Needle,dual Safety,diabetc40$2,405
Humalog Kwikpen U-100Insulin Lispro19$2,321
Atorvastatin Calcium199$2,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$55,91392 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$35,34828 claims
GSKTrelegy Ellipta, Anoro Ellipta$19$24,31940 claims
Boehringer IngelheimJardiance, Tradjenta$35$23,92233 claims
AstraZenecaFarxiga$87$12,77517 claims
MerckJanuvia$15$7,85718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Irwin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →